The list price of the therapy for A.L.S., Relyvrio, is $158,000 a year. To make matters worse, the drug was approved by the Food and Drug Administration even though the agency’s analysis concluded there was not yet sufficient evidence that the medication could help patients live longer or slow the rate at which they lose functions like muscle control, speaking or breathing without assistance.

Access to HCPs has declined steadily, with about 49 percent of Physicians in the U.S. placing restrictions on visits from pharma sales reps. But according to Fierce Pharma, “more than 8 in 10 (83%) of HCPs say the content they’re getting from pharma companies is more relevant now than before COVID-19, and they likely have more time to read it. Three-quarters said they’d seen fewer patients over the past year, and 61% said they have more available time than they did pre-pandemic”. You can launch a drug digitally but..

  • According to the Lancet, “from 1995 to 2014, there were 14,672,409 incident cases for 30 types of cancer. Incidence significantly increased for six of 12 obesity-related cancers in young adults (25–49 years), with steeper rises in younger generations.
  • The risk of cancer is increasing for half of the obesity-related cancers in young adults, with the increase steeper at progressively younger ages.

The obesity market is expected to grow into a $54B market, but many questions remain, including the cost of $1,000-$1,500 a month and side effects, including nausea or diarrhea. After years of failed drugs, a new class of weight loss drugs reached the market last year — proving to be highly effective, but we don’t know about long-term side effects.

Until 1973, federal law did not encourage health insurance providers from functioning under a profit motive. By the late 1990s, 80 percent of MCOs were for-profit organizations, and only 68 percent or less of insurance premiums went toward medical care. The remainder was paid for MCO executives’ and salespersons’ salaries. In retrospect, it was a huge mistake.